The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://bushraaotw179071.p2blogs.com/37365240/retatrutide-vs-tirzepatide-a-comparative-analysis